Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

enables marketing of Celacade for the treatment of chronic heart

failure in the 27 member countries of the E.U. Celacade is also the

only CE Mark approved product that specifically targets the

destructive chronic inflammation underlying the development and

progression of heart failure. Under the CE Mark in Europe, Celacade

is approved for the treatment of all NYHA Class II patients and NYHA

Class III, & IV heart failure patients who do not have a history of

prior heart attack. We currently expect that the first clinical sites

in Germany will be in a position to offer Celacade therapy to

patients in April 2008.

Due to the fact that we recently provided a detailed update on corporate activities during our Annual Shareholders' Meeting on March 25, 2008, we will not host a conference call at this time. A replay of the Annual Shareholders' Meeting presentation is available at http://www.vasogen.com.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements containe
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/29/2014)... A major challenge before new biotechnology ... realm of Boston-Cambridge, is gaining visibility that can lead ... the Director of Boston’s Adult Stem Cell Technology Center, ... visibility of his company an important priority since he ... to a social media marketing campaign launched ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... the food processing industry, is asking industry professionals to ... comparison of the E2 soap they’re currently using to ... Soap . Hand hygiene is critical to fighting ... processing environment. Six key criteria are identified to evaluate ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Aug. 20 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... for sale of ProteoSolve-SB, a novel, pressure cycling,technology ... of nucleic acids (DNA and RNA), proteins, and,lipids ... laboratory research.,This patent-pending kit was released earlier this ...
... 20 CEL-SCI CORPORATION,(Amex: CVM ) reports financial results ... The Company,s loss from operations for the quarter ended June ... same quarter in 2007.,The Company,s loss from operations for the ... of $7,368,779 during the same nine months in,2007., The ...
... second,webinar in its training and education series. The 30-minute ... of Mice, will be,held on August 27th at 11:00 ... for in vivo,imaging of small animals due to the ... that occur at NIR wavelengths., LI-COR, a leader ...
Cached Biology Technology:Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies 2Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies 3Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 2CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 5LI-COR August 27th On-Line Webinar Introduces New Approach to Small Animal In Vivo Imaging 2
(Date:8/29/2014)... prolific bloomer Emiliania huxleyi , can grow without ... contradicts the common view that E. huxleyi ... of thiamine in the ocean to survive. , "It,s ... says CIFAR Senior Fellow Alexandra Worden , co-author ... fellows John Archibald (Dalhousie University), Adrin ...
(Date:8/28/2014)... is now available from the Lady Bird Johnson Wildflower ... identifying harmful non-native plant, insect and other invasive species ... cause about $137 billion in economic and other damage ... native plants and more. , "By having streamlined tools ... species occur, we,re more likely to catch these threats ...
(Date:8/28/2014)... German . The ... a striking pattern of blue stripes alternating with golden stripes. ... and yellow cells emerge during growth in the skin of ... to compose the characteristic colour pattern. ,While it ... to form proper stripes, the embryonic origin of the pigment ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... populating the growing brain, neural stem cells must strike a ... the cells multiply to provide plenty of starting materials ... If the stem cells proliferate too much, they could ... proliferate too little, there may not be enough cells to ...
... / b3c newswire / - KINAXO Biotechnologies GmbH ... service portfolio. KinAffinity provides invaluable information about a ... of interest. It simultaneously determines affinities for native ... overcomes the limitations of traditional biochemical assays that ...
... of researchers from the University of Maryland Center for ... study to forecast the effects of environmental change on ... by a $620,000 grant from the National Science Foundation, ... Preserve near Alexandria, Virginia. "Freshwater marshes are integral ...
Cached Biology News:UNC study pinpoints gene controlling number of brain cells 2KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
MAb to Desmoplakin I & II Desmoplakin I & II...
... conjuction with Annexin V-FITC to distinguish cells ... apoptosis (Annexin V positive, PI negative) from ... apoptosis or already dead (Annexin V-FITC positive, ... orange range of the spectrum using a ...
Biology Products: